Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-301 (zalifrelimab) in recurrent NMIBC
NCT05375903Phase 1Completed
- Sponsor
- UroGen Pharma
- Start
- Jun 2022
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of zalifrelimab in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by UroGen Pharma. Primary endpoints: Dose-Limiting Toxicities at 15 months, Treatment-Emergent Adverse Events at 15 months and 3 more. Started Jun 2022; status: completed.
02
Drugs
zalifrelimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05375903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375903.